MYSTERIOUS: 4 - You Need To See This

Read How Analysts Reacted To Jack In The Box's Q2 Results

Analysts lowered the price target of Jack In The Box Inc (NASDAQ:JACK) following the company's Q2 results. Wedbush analyst Nick Setyan lowered the price target to $90 (35% upside) from $110 and maintained Outperform rating on the stock. The analyst thinks JACK's current valuation discounts an overly pessimistic view of the management's ability to…

Benzinga · May 27, 2022

Executives Buy Around $3.5M Of 2 Stocks

Although Dow Jones futures traded sharply lower this morning on Monday, there were a few notable insider trades.

Benzinga · May 9, 2022

Another Analyst Sets Bullish Tone On NVIDIA, Sees Considerable Upside

New Street analyst Pierre Ferragu upgraded NVIDIA Corp (NASDAQ:NVDA) to Buy from Neutral with a price target of $280 (30.2% upside). Ferragu saw an attractive valuation, greater visibility on the "crypto-winter risk," and the company's robust data center outlook.  Ethereum's hash rate quadrupled between October 2020 and January 2022, likely boosting Nvidia's FY22 gaming revenues…

Benzinga · Apr 13, 2022

Analysts Bump Up Costco Price Target Post March Sales Results

Truist analyst Scot Ciccarelli raised the price target on Costco Wholesale Corp (NASDAQ: COST) to $634 from $603 and kept a Buy rating on the shares.

Benzinga · Apr 7, 2022

Read How Analysts Reacted To Blend Labs' Q4 Results

Analysts mainly slashed the price targets or downgraded the rating on Blend Labs Inc (NYSE:BLND) post Q4 results. KeyBanc analyst Josh Beck lowered the price target to $6 from $10 (26% upside) and kept an Overweight.  The company's FY22 revenue forecast was well below the Street's $343.8 million, reflecting the negative impact of higher rates…

Benzinga · Apr 1, 2022

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal.  Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

Benzinga · Mar 30, 2022

GitLab Shares Pop As Analysts See Sharp Upside Post Q4

Analysts painted sharp upside to GitLab Inc (NASDAQ:GTLB) post strong Q4 results that included a notable top-line beat and FY23 guidance ahead of Street expectations. Truist analyst Joel Fishbein lowered the PT to $105 from $175 (217.2% upside) and kept a Buy, citing the change in discount rate assumptions since the IPO.  KeyBanc analyst Michael Turits lowered…

Benzinga · Mar 15, 2022

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Benzinga · Mar 9, 2022

Here's Why Roku Plunged Below 52-Week Low Today

Analysts slashed their price targets on Roku Inc (NASDAQ:ROKU) post Q4 results. Pivotal Research analyst Jeffrey Wlodarczak downgraded to Sell from Hold with a PT of $95, down from $350 (34.4% downside).  The company reported an "overall mixed" Q4 as it issued a lower than forecast 2022 revenue outlook and decided to "massively ramp" operating expenses,…

Benzinga · Feb 18, 2022

Here's Why Piper Sandler Is Optimistic On Nvidia

Piper Sandler analyst Harsh Kumar reiterated an Overweight rating and $350 price target on NVIDIA Corp (NASDAQ:NVDA). Nvidia could be a big winner this earnings season, with profits driven by solid performance in the chip maker's gaming and data center businesses, Kumar said. "We are looking for a significant beat and raise when the company…

Benzinga · Feb 15, 2022